Compare BioNano Genomics Inc (BNGO) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.06. The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | EMB | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Fixed Income |
52-Week High | $4.92 | $97.74 |
52-Week Low | $1.06 | $92.95 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
EMB trades at $94.99 with minimal daily movement (+0.16%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces significant selling pressure with support and resistance clustered around $95. Recent corporate actions include scheduled dividend payments through mid-2026, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators favoring sellers and limited fundamental data available. Investment opportunity centers on dividend income stream, while risks include emerging market sovereign default exposure and Federal Reserve policy sensitivity. Analyst sentiment suggests limited upside potential beyond current yield returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
